Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status

PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL Clinical Trial

Status Recruiting

Clinical Trial Summary

The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.

Clinical Trial Description

THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS:

1. GENETIC (FOR CYP450 2C19)

2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY)

3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD ;

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL

• NCT number: NCT01210248
• Study type: Observational
• Source: Assaf-Harofeh Medical Center
• Contact: ADINA BAR HAIM, PhD
• Phone: 08-9779897
• Email: dinab@asaf.health.gov.il
• Status: Recruiting
• Phase: N/A
• Start date: September 2010